Gary Charles Robb. - 01 Jun 2026 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Reporting relationship: Chief Business Officer
Issuer ticker: CORT
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 19:15:19 UTC
Prior SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.

Key filing fact

Gary Charles Robb. filed Form 4 for CORCEPT THERAPEUTICS INC (CORT) on 03 Jun 2026.

Key facts

This page summarizes Gary Charles Robb.'s Form 4 filing for CORCEPT THERAPEUTICS INC (CORT).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jun 2026, 19:15.

Change

Previous filing in this sequence was filed on 15 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001529655 Primary reporting owner

Robb Gary Charles

Relationship: Chief Business Officer
Address: C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Signature: /s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.
Signature date: 03 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CORT transaction

Common Stock

Award

Transaction value
Shares: +776
Change %: +3.2%
Price: $70.44^*
Shares after: 25,263
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

CORT transaction

Common Stock

Award

Transaction value
Shares: +776
Change %: +3.1%
Price: $0.000000^*
Shares after: 26,039
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F3, F4

CORT transaction

Common Stock

Tax liability

Transaction value
Shares: -358
Change %: -1.4%
Price: $70.44^*
Shares after: 25,681
Date: 02 Jun 2026
Ownership: Direct
Footnotes: F5, F6, F7

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,571
Date: 01 Jun 2026
Ownership: Custodial Account for Child
Footnotes: F8

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,571
Date: 01 Jun 2026
Ownership: Custodial Account for Child
Footnotes: F9

CORT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 49,716
Date: 01 Jun 2026
Ownership: Gary Charles Robb TTE Robb Revocable Trust
Footnotes: F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.

Footnote F2

In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

Footnote F3

Includes 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F4

Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Footnote F5

These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

Footnote F6

The closing price on June 1, 2026 was used to calculate the withholding obligation.

Footnote F7

Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, and 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Footnote F8

These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Footnote F9

These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Footnote F10

These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.